OKYO Pharma Limited
NASDAQ:OKYOBiotechnology
+$0.01 today
- Market cap
- $57.73M
- Beta
- 0.02
- P/E (TTM)
- -12.8
- EPS (TTM)
- -$0.12
Volume 0.24M
Average 0.07M
OKYO Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
OKYO Pharma LimitedNASDAQ: OKYO
Cash & Equivalents · Q2 FY2026 · quarter ended Sep 2025
Cash & equivalents rises 327.5% from a year ago
Cash & equivalents stood at $4.22M at the end of Q2 FY2026, up 327.5% from a year earlier. Over 3 fiscal years it compounded at -16.7% a year.
Context
- Cash & equivalents amounted to 90.9% of total assets at the end of Q2 FY2026, up 56.0 pp from a year earlier.
- Cash & equivalents increased in 2 of the last 3 fiscal years.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +327.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 1.56M USD
- Year-over-year change
- +88.8%
- 4-year CAGR
- -31.0%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-03-31 | 1.56M | +88.8% |
| FY2024 | 2024-03-31 | 826.85K | -79.6% |
| FY2023 | 2023-03-31 | 4.05M | +49.8% |
| FY2022 | 2022-03-31 | 2.7M | -60.8% |
| FY2021 | 2021-03-31 | 6.89M | — |
Cash & Equivalents vs competitors
How OKYO compares with its peers on the latest reported figures
- OKYO's Sep 2025 cash & equivalents of $4.22M is the 9th highest of the 10 companies compared; the peer median is $31.93M.
- Its year-over-year change of +327.5% is the 2nd highest of 10, against a peer median of -39.6%.
- Cash & equivalents amounts to 90.9% of total assets for OKYO, versus a peer median of 27.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $79.25M | +397.8% | +91.2% | 82.7% | |
| Mar 2026 | $66.52M | -54.3% | -19.3% | 30.5% | |
| Mar 2026 | $50.72M | +42.8% | +99.1% | 95.2% | |
WHWKWhitehawk Therapeutics Inc | Mar 2026 | $34.79M | -84.7% | -1.3% | 27.3% |
| Mar 2026 | $31.93M | -23.8% | -5.8% | 12.6% | |
| Mar 2026 | $22.19M | -75.9% | +10.5% | 11.0% | |
| Mar 2026 | $10.14M | -40.0% | -3.9% | 17.3% | |
| Mar 2026 | $5.94M | -39.6% | -34.3% | 27.4% | |
| Sep 2025 | $4.22M | +327.5% | -16.7% | 90.9% | |
| Dec 2025 | $4.01M | +7.7% | -39.5% | 34.9% | |
| Peer median (excluding OKYO) | $31.93M | -39.6% | -3.9% | 27.4% | |
Competitors are the stored peer set for OKYO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Mar 2021 | FY2022 Mar 2022 | FY2023 Mar 2023 | FY2024 Mar 2024 | FY2025 Mar 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 6.89M | 2.7M | 4.05M | 826.85K | 1.56M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 4.5K | 883.44K | 980.08K | 580.94K | 1.89M |
| Inventory | 34 | (1.49K) | 170.31K | 0 | 0 |
| Other Current Assets | 71.75K | 1.49K | (170.31K) | 0 | 0 |
| Total Current Assets | 6.99M | 4.3M | 5.2M | 1.54M | 3.68M |
| Property, Plant & Equipment (Net) | 104.64K | 5.23K | 7.22K | 3.35K | 2.04K |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Assets | 104.64K | 5.23K | 7.22K | 3.35K | 2.04K |
| Total Assets | 7.09M | 4.3M | 5.2M | 1.54M | 3.68M |
| Account Payables | 210.99K | 517.67K | 1.02M | 6.13M | 7.9M |
| Short-term Debt | 34.14K | 0 | 2.22M | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 1.43M | 323.06K | 1.29M | 7.1M | 9.04M |
| Total Current Liabilities | 1.71M | 1.35M | 7.26M | 7.42M | 9.23M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 64.61K | 0 | 0 | 0 | 0 |
| Total Liabilities | 1.77M | 1.35M | 7.26M | 7.42M | 9.23M |
| Common Stock | 0 | 123.98M | 0 | 143.11M | 0 |
| Retained Earnings | (99.4M) | (112.43M) | (125.7M) | (142.52M) | (143.02M) |
| Accumulated OCI | 12.82M | (11.01M) | (7.74M) | (11.31M) | (11.47M) |
| Other Stockholders Equity | (1) | 2.41M | 173 | 4.84M | 2.23M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 5.32M | 2.95M | (2.05M) | (5.88M) | (5.55M) |
| Total Debt | 98.76K | 0 | 2.22M | 0 | 0 |
| Net Debt | (6.79M) | (2.7M) | (1.83M) | (826.85K) | (1.56M) |
OKYO Pharma Limited
NASDAQ:OKYO
Intrinsic Alpha fair value
Locked
Current Price
$1.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.